A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Gynecologic Oncology

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2007.01.019PMID 17306350PMCID PMC1931832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure–Function Relationships and Molecular Recognition

  2005cited by this paper
• Sex steroid-dependent angiogenesis in uterine endometrial cancers.

  2005cited by this paper
• Properties of thalidomide and its analogues: Implications for anticancer therapy

  2005cited by this paper
• VEGF and Its Receptors (flt-1 and KDR/flk-1) as Prognostic Indicators in Endometrial Carcinoma

  2005cited by this paper
• Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2004cited by this paper
• Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.

  2004cited by this paper
• Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

  2004cited by this paper
• Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group

  2003cited by this paper
• Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.

  2002cited by this paper
• [Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma].

  2002cited by this paper
• [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].

  2002cited by this paper
• Clinical translation of angiogenesis inhibitors

  2002cited by this paper
• Plasma levels of endothelial protein C receptor respond to anticoagulant treatment.

  2002cited by this paper
• Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells.

  2002cited by this paper
• Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.

  2001cited by this paper
• Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma.

  2001cited by this paper
• Expression and Anticoagulant Function of the Endothelial Cell Protein C Receptor (EPCR) in Cancer Cell Lines

  2001cited by this paper
• Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival.

  2001cited by this paper
• Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer.

  2001cited by this paper
• The TF:VIIa Complex: Clinical Significance, Structure-function Relationships and Its Role in Signaling and Metastasis

  2001cited by this paper
• The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma

  2001cited by this paper
• Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [Expression of basic fibroblastic growth factor and microvessel density in endometrial carcinoma].

  2000influential reference
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.

  2000cited by this paper
• Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels.

  2000cited by this paper
• Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma.

  2000cited by this paper
• Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

  1999cited by this paper
• Regulation and functions of the protein C anticoagulant pathway.

  1999cited by this paper
• Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a

  1999cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999influential reference
• Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.

  1999cited by this paper
• Plasma Levels of Endothelial Cell Protein C Receptor Are Elevated in Patients With Sepsis and Systemic Lupus Erythematosus : Lack of Correlation With Thrombomodulin Suggests Involvement of Different Pathological Processes

  1998cited by this paper
• Involvement of platelets in tumour angiogenesis?

  1998cited by this paper
• Optimal flexible designs in phase II clinical trials.

  1998cited by this paper
• Independent prognostic importance of microvessel density in endometrial carcinoma.

  1998cited by this paper
• Independent prognostic importance of microvessel density in endometrial carcinoma

  1998cited by this paper
• Angiogenesis in endometrial cancer.

  1998cited by this paper
• Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes.

  1998cited by this paper
• Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.

  1997cited by this paper
• Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma

  1995cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

  1979cited by this paper
• Clinical experiences with thalidomide in patients with cancer

  1965cited by this paper

• PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer

  2024cites this paper
• Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy

  2024cites this paper
• Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study

  2023cites this paper
• Recurrent Endometrial Cancer: Local and Systemic Treatment Options

  2021cites this paper
• Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer

  2021cites this paper
• Endometrial Cancer

  2020cites this paper
• A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide

  2020cites this paper
• Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.

  2020cites this paper
• Atlas of Hysteroscopy

  2020cites this paper
• Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives.

  2020cites this paper
• Old wine in new bottles: Drug repurposing in oncology.

  2019cites this paper
• Targeted Therapy in Management of Endometrial Cancer

  2019cites this paper
• Endometrial Cancer: Obesity, Genetics, and Targeted Agents.

  2019cites this paper
• Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.

  2019cites this paper
• Management Strategies for Recurrent Endometrial Cancer

  2018cites this paper
• A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.

  2018cites this paper
• Endometrial cancer: Molecular markers and management of advanced stage disease.

  2018cites this paper
• Endometrial Cancer

  2017cites this paper
• Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review

  2017cites this paper
• New therapies for advanced, recurrent, and metastatic endometrial cancers

  2017cites this paper
• Targeting fibroblast growth factor pathways in endometrial cancer.

  2017cites this paper
• Targeted Therapy and Prevention of Endometrial Cancer

  2017cites this paper
• Recent Advances in Endometrial Cancer

  2017cites this paper
• Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer

  2017cites this paper
• Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.

  2016cites this paper
• Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

  2016cites this paper
• Immunotherapy and Uterine Cancer

  2016cites this paper
• Targeting angiogenesis in endometrial cancer - new agents for tailored treatments

  2016influential citation
• Developmental Therapeutics for Gynecologic Cancers: An Overview

  2016cites this paper
• Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.

  2016cites this paper
• Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase

  2015cites this paper
• Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers

  2015cites this paper
• Advances in the Management of Recurrent Endometrial Cancer

  2015cites this paper
• Endometrial cancer: redefining the molecular-targeted approach

  2015cites this paper
• Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

  2015cites this paper
• Practice Bulletin No. 149: Endometrial Cancer

  2015cites this paper
• Past, Present and Future Perspectives on the Management of Endometrial Cancer— A Comprehensive Review

  2015cites this paper
• Second-Line Therapy for Endometrial Cancer: The Need for Better Options.

  2015cites this paper
• Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

  2015cites this paper
• Endometriyum Kanserinde Targeted Terapiler

  2015cites this paper
• Targeted therapy in gynecologic cancers: Ready for prime time?

  2015cites this paper
• A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

  2015cites this paper
• Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers

  2014cites this paper
• Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

  2014cites this paper
• A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

  2014cites this paper
• A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.

  2014cites this paper
• Targeted Therapies in Endometrial Cancer

  2014cites this paper
• Referrals to phase I clinical trials in a gynecologic oncology unit.

  2014cites this paper
• A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

  2014cites this paper
• A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

  2014cites this paper
• Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan

  2014cites this paper
• Molecular targets and targeted therapy

  2014cites this paper
• Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma.

  2013cites this paper
• Multidisciplinary treatment of early stage endometrial cancer.

  2013cites this paper
• Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010.

  2013cites this paper
• Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option

  2013cites this paper
• Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

  2013cites this paper
• Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells

  2013cites this paper
• Current status of molecular-targeted drugs for endometrial cancer (Review)

  2013cites this paper
• Zielgerichtete Therapieansätze beim Endometriumkarzinom

  2012cites this paper
• Targeted Therapy and Molecular Genetics

  2012cites this paper
• Personalized care in uterine cancer.

  2012cites this paper
• Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

  2012cites this paper
• A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

  2012cites this paper
• New biologic agents for the treatment of gynecologic cancers.

  2012cites this paper
• Personalized therapy in endometrial cancer: Challenges and opportunities

  2012cites this paper
• Molecular targets and targeted therapeutics in endometrial cancer

  2012cites this paper
• Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2011cites this paper
• Developments in the systemic treatment of endometrial cancer.

  2011cites this paper
• Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.

  2011cites this paper
• Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.

  2011cites this paper
• Emerging therapeutic targets in endometrial cancer

  2011cites this paper
• Thalidomide and irradiation combination therapy increases substance P levels in vitro.

  2011cites this paper
• Recent Advances in Anti-Angiogenic Therapy of Cancer

  2011cites this paper
• Serum levels of VEGF and VEGF-C in patients with endometrial cancer.

  2011cites this paper
• Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part I

  2011cites this paper
• Controversies in the Management of Endometrial Cancer

  2010cites this paper
• Promising novel therapies for the treatment of endometrial cancer.

  2010cites this paper
• Does the progression‐free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?

  2010cites this paper
• VEGF Levels in Women with Gynaecological Cancers

  2010cites this paper
• A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.

  2010cites this paper
• Emerging drugs in endometrial cancers

  2010cites this paper
• Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?

  2010cites this paper
• Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2009cites this paper
• Systemic therapy for recurrent endometrial cancer: a review of North American trials

  2009cites this paper
• The antiangiogenic effect of thalidomide on occult liver metastases: An in vivo study in mice

  2009cites this paper
• Assessment of soluble angiogenic markers in pancreatic cancer.

  2008cites this paper
• Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

  2008cites this paper
• Combination therapy of tyrosine kinase receptor inhibitor TSU-68 (SU6668) and paclitaxel inhibits subcutaneous xenografts of endometrial cancer.

  2008cites this paper
• Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2008cites this paper
• Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

  2008cites this paper
• Obstetrics & Gynecology & Women's Health Institute 2007 Publications

  2007cites this paper
• A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

  2007cites this paper
• Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency.

  2007cites this paper
• Recent Advances in Endometrial Cancer [version 1; peer review: 2 approved]

  year unknowncites this paper